Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.
OBJECTIVE
The use of bisphosphonates is well established for the treatment of patients with metastatic bone disease, osteoporosis, and Paget's disease. Osteonecrosis of the mandible or maxilla associated with the use of bisphosphonates is a newly described entity never before discussed in the otolaryngology literature. In this paper, we review a series of patients diagnosed with osteonecrosis, all treated with new generation bisphosphonates. Our objective is to inform and educate others, particularly otolaryngologists/head and neck surgeons, about this drug induced entity, a condition that should be recognized early to avoid potential devastating consequences.


METHODS
Retrospective chart review of a series of patients from a tertiary referral center.


METHODS
Pathology reports of specimens submitted from either the mandible or maxilla were reviewed from the previous 12 months. Any patient diagnosed with osteonecrosis without evidence of metastatic disease at that site was included; those with a previous history of radiation therapy were excluded. Each patient's medical history and profile were reviewed.


RESULTS
Twenty-three patients were identified with osteonecrosis of the mandible or maxilla. All of these were associated with the use of new generation bisphosphonates: zolendronate (Zometa, Novartis), pamidronate (Aredia, Novartis), and alendronate (Fosamax, Merck). Eighteen patients with known bone metastases had been treated with the intravenous form, whereas five patients with either osteoporosis or Paget's disease were using oral therapy. Patients typically presented with a nonhealing lesion, often times the result of previous dental intervention. Although the majority of these patients were treated with conservative surgical debridement, we present a case requiring a near total maxillectomy.


CONCLUSIONS
Drug induced osteonecrosis of the mandible or maxilla has been recently recognized as a sequelae of treatment with the new generation of bisphosphonates. Most patients can be treated with conservative surgical debridement and cessation of bisphosphonate therapy, whereas a few may require radical surgical intervention. Other recommendations include regimented prophylactic care with an assessment of dental status before the administration of bisphosphonates, avoidance of dental procedures, and close monitoring of oral hygiene.
Farrugia
Matthew C
MC
Department of Otolaryngology, Botsford General Hospital, Farmington Hills, Michigan 48336, USA. farrugi5@msu.edu
Summerlin
Don-John
DJ
Krowiak
Edward
E
Huntley
Tod
T
Freeman
Stephen
S
Borrowdale
Richard
R
Tomich
Charles
C
D001707:Biopsy, Needle; D001859:Bone Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D003646:Debridement / Q000379:methods; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007262:Infusions, Intravenous; D008334:Mandible / Q000473:pathology / Q000601:surgery; D008437:Maxilla / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D019647:Oral Surgical Procedures / Q000379:methods; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery*; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D004164:Diphosphonates